Adding pembrolizumab (Keytruda) to standard-of-care chemotherapy, followed by maintenance pembrolizumab, led to a reduction in risk of disease progression or death in patients with advanced or recurr. Read More
In 2 MMR Cohorts, Pembrolizumab/Chemotherapy Benefits Survival in Advanced Endometrial Cancer – Targeted Oncology
/cloudfront-us-east-1.images.arcpublishing.com/gray/4MVHA2WZO5C3VEFG6ME4ACC2HA.PNG)
